U.S. Markets close in 1 hr 57 mins
  • S&P 500

    4,437.01
    -45.72 (-1.02%)
     
  • Dow 30

    34,520.23
    -195.16 (-0.56%)
     
  • Nasdaq

    13,954.01
    -200.01 (-1.41%)
     
  • Russell 2000

    2,013.12
    -10.92 (-0.54%)
     
  • Crude Oil

    85.01
    -0.54 (-0.63%)
     
  • Gold

    1,832.60
    -10.00 (-0.54%)
     
  • Silver

    24.38
    -0.34 (-1.36%)
     
  • EUR/USD

    1.1347
    +0.0030 (+0.2610%)
     
  • 10-Yr Bond

    1.7560
    -0.0770 (-4.20%)
     
  • Vix

    27.41
    +1.82 (+7.11%)
     
  • GBP/USD

    1.3564
    -0.0036 (-0.2672%)
     
  • USD/JPY

    113.6820
    -0.4180 (-0.3663%)
     
  • BTC-USD

    38,343.62
    -4,623.23 (-10.76%)
     
  • CMC Crypto 200

    901.08
    +658.40 (+271.30%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ALIM

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on Tuesday September 15, 2020 at 3:30 PM ET. To listen to the conference live, please sign up at https://wsw.com/webcast/hcw7/alim/1592203.

An archived presentation will be available from September 16th on the Alimera website at https://investors.alimerasciences.com/alim/corporate_documents?type=100510&template=most_recent_redirect

In addition, Mr. Eiswirth is available for virtual one-on-one meetings from September 14 – 16, 2020. To schedule a meeting please contact the conference coordinator at meetings@hcwco.com.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com

For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com